Latest News
TheraCryf advances Ox-1 programme to clinical stage following successful GMP manufacture
20 April 2026 - TheraCryf plc (AIM: TCF), a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, revealed on Monday that it has completed the Good Manufacturing Practice (GMP) production of over 2kg of cl...
Accent Therapeutics presents ATX-295 data at AACR Annual Meeting 2026
20 April 2026 - Clinical-stage biopharmaceutical company Accent Therapeutics on Friday presented preclinical data supporting its potentially best-in-class KIF18A inhibitor, ATX-295, at the American Association for Cancer Research (AACR) Annual Meetin...
10x Genomics introduces new in situ spatial biology platform
20 April 2026 - Life science technology company 10x Genomics Inc (Nasdaq:TXG) on Saturday introduced Atera, an in situ spatial biology platform designed to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented sca...
Lundbeck presents new real-world data on VYEPTI (eptinezumab) at AAN 2026
20 April 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) on Sunday presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance of eval...
Whitehawk Therapeutics presents ADC preclinical data at AACR 2026
...